Talk Radioisotopes: Going Nuclear on Cancer
Talk Radioisotopes: Going Nuclear on Cancer
Podcast Description
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
Podcast Insights
Content Themes
The podcast centers on the evolving field of radiopharmaceuticals, covering essential topics such as targeted radiotherapies, regulatory challenges, and isotope supply chains. For example, episodes may delve into the implications of new isotopes for personalized cancer treatments or the impact of pharmaceutical companies entering the market.
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed?
Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape.
Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer.
Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer.
Brought to you by the team at Nusano.
In this episode of Talk Radioisotopes, Paul Schrimpf, Proprietor and Entrepreneur at Cyrall, unpacks what it takes to build and scale a radiopharmaceutical business. With a background spanning Accenture, Prophet, and leadership roles advising top healthcare organizations, Paul draws on deep experience across strategy, marketing, and team development to lay out what radiopharma innovators can learn from the broader B2B and life sciences sectors. He explains why too many startups fall in love with their technology before identifying a buyer, and why clarity, not complexity, is the foundation of effective communication.
Paul also explores how AI is reshaping early-stage strategy—not by replacing decision-makers, but by accelerating hypothesis development, sharpening messaging, and driving customer-centric thinking. He shares practical frameworks for using tools like ChatGPT to refine go-to-market models, stress-test assumptions, and identify real buyers, not just theoretical markets.
The conversation then pivots to commercialization strategy, where Paul critiques outdated pharma marketing playbooks and highlights the untapped potential of personalization and digital targeting. He also challenges old-school sales mentalities, urging founders and go-to-market teams to prioritize listening over pitching. Whether you’re building a radiopharma company or advising one, this episode is packed with tactical insights into what it takes to succeed in today’s healthcare environment.
——–
Time Stamps:
- *(4:45) Business Comes Down to People
- *(8:15) Addressing Unmet Needs and the Biggest Mistakes Startups Make
- *(21:20) What Pharma Marketing Still Gets Wrong
- *(24:50) Where is the Consumer?
- *(32:00) What Space is Radiopharma in the Future?
——–
‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.
——–
Links:
——-
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.